Premium
Reversal of tacrolimus‐related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient
Author(s) -
TurskaKmieć Anna,
Jankowska Irena,
Pawłowska Joanna,
Kaliciński Piotr,
Kawalec Wanda,
Tomyn Małgorzata,
Markiewicz Małgorzata,
Teisseyre Joanna,
Czubkowski Piotr,
Rękawek Joanna,
Socha Jerzy
Publication year - 2007
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/j.1399-3046.2006.00633.x
Subject(s) - medicine , tacrolimus , hypertrophic cardiomyopathy , calcineurin , liver transplantation , immunosuppression , sirolimus , discontinuation , heart transplantation , muscle hypertrophy , complication , transplantation , organ transplantation , cardiology
Tacrolimus (Tac)‐related hypertrophic cardiomyopathy (HCM) has been reported to be an unusual but serious complication affecting pediatric patients after solid organ transplantation. Herein, we present a case of young liver transplant recipient with Tac‐induced HCM, treated by discontinuation of Tac followed by conversion to rapamycin (Rap). Our case report points out the potential but rather low risk of HCM during Tac immunosuppression in pediatric liver transplants and demonstrates that replacement of calcineurin inhibitors with mammalian target of Rap (mTOR) inhibitors may be an efficacious therapeutic tool to effect regression of established cardiac hypertrophy.